Free Access
Med Sci (Paris)
Volume 31, Number 1, Janvier 2015
Page(s) 28 - 31
Section Nouvelles
Published online 06 February 2015
  1. Bedard PL, Hansen AR, Ratain MJ, Siu LL. Tumour heterogeneity in the clinic. Nature 2013 ; 501 : 355–364. [Google Scholar]
  2. Bray F, Jemal A, Grey N, et al. Global cancer transitions according to the human development index (2008–2030): a population-based study. Lancet Oncol 2012 ; 13 : 790–801. [CrossRef] [PubMed] [Google Scholar]
  3. Holohan C, Van Schaeybroeck S, Longley DB, Johnston PG. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 2013 ; 13 : 714–726. [CrossRef] [PubMed] [Google Scholar]
  4. Burrell RA, McGranahan N, Bartek J, Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature 2013 ; 501 : 338–345. [CrossRef] [PubMed] [Google Scholar]
  5. Roux J, Hafner M, Bandara S, et al. Fractional killing in response to TRAIL and therapeutic antibody agonists arises from cell-to-cell variability in overcoming a caspase-8 activity threshold. FEBS J 2014 ; 281 : 526. [Google Scholar]
  6. Spencer SL, Gaudet S, Albeck JG, et al. Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis. Nature 2009 ; 459 : 428–432. [CrossRef] [PubMed] [Google Scholar]
  7. Gaudet S, Spencer SL, Chen WW, Sorger PK. Exploring the contextual sensitivity of factors that determine cell-to-cell variability in receptor-mediated apoptosis. PLoS Comput Biol 2012 ; 8 : e1002482. [CrossRef] [PubMed] [Google Scholar]
  8. Newman RH, Fosbrink MD, Zhang J. Genetically encodable fluorescent biosensors for tracking signaling dynamics in living cells. Chemical Reviews 2011 ; 111 : 3614–3666. [CrossRef] [PubMed] [Google Scholar]
  9. Chen WW, Niepel M, Sorger PK. Classic and contemporary approaches to modeling biochemical reactions. Genes Dev 2010 ; 24 : 1861–1875. [CrossRef] [PubMed] [Google Scholar]
  10. Luan D, Zai M, Varner JD. Computationally derived points of fragility of a human cascade are consistent with current therapeutic strategies. PLoS Comput Biol 2007 ; 3 : e142. [Google Scholar]
  11. Beckman RA, Schemmann GS, Yeang CH. Impact of genetic dynamics and single-cell heterogeneity on development of nonstandard personalized medicine strategies for cancer. Proc Natl Acad Sci USA 2012 ; 109 : 14586–14591. [CrossRef] [Google Scholar]
  12. Flusberg DA, Roux J, Spencer SL, Sorger PK. Cells surviving fractional killing by TRAIL exhibit transient but sustainable resistance and inflammatory phenotypes. Mol Biol Cell 2013 ; 24 : 2186–2200. [CrossRef] [PubMed] [Google Scholar]
  13. Billaud M.. L’hétérogénéité intratumorale : un obstacle darwinien à la médecine personnalisée ? Med Sci (Paris) 2012 ; 28 : 1116–1119. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  14. Jordan B.. Hétérogénéité des tumeurs : l’apport du séquençage sur cellules individuelles. Med Sci (Paris) 2014 ; 30 : 1184–1186. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  15. Xia X, Owen MS, Lee RE, Gaudet S. Cell-to-cell variability in cell death: can systems biology help us make sense of it all ? Cell Death Dis 2014 ; 5 : e1261. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.